C-terminal Src kinase | Csk family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

C-terminal Src kinase

Target id: 1994

Nomenclature: C-terminal Src kinase

Abbreviated Name: CSK

Family: Csk family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

   GtoImmuPdb view: ON :     C-terminal Src kinase has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 450 15q24.1 CSK C-terminal Src kinase
Mouse - 450 9 B Csk c-src tyrosine kinase
Rat - 450 8 q24 Csk C-terminal Src kinase
Previous and Unofficial Names
tyrosine-protein kinase CSK | c-src tyrosine kinase | CSK, non-receptor tyrosine kinase
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
RefSeq Nucleotide
RefSeq Protein
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Resolution:  2.4Å
Species:  Human
References:  5
Enzyme Reaction
EC Number:

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
NG-25 Hs Inhibition 7.3 pIC50 7
pIC50 7.3 (IC50 5.64x10-8 M) [7]
apatinib Hs Inhibition 6.3 pIC50 8
pIC50 6.3 (IC50 5.3x10-7 M) [8]
Description: Assay used apatinib mesylate (YN968D1)
PP1 Hs Inhibition 6.3 pIC50 2
pIC50 6.3 (IC50 5.2x10-7 M) [2]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
Reference: 3,10

Key to terms and symbols Click column headers to sort
Target used in screen: CSK
Ligand Sp. Type Action Affinity Units
dasatinib Hs Inhibitor Inhibition 9.0 pKd
bosutinib Hs Inhibitor Inhibition 7.5 pKd
PD-173955 Hs Inhibitor Inhibition 7.2 pKd
foretinib Hs Inhibitor Inhibition 6.9 pKd
tamatinib Hs Inhibitor Inhibition 6.8 pKd
lestaurtinib Hs Inhibitor Inhibition 6.6 pKd
staurosporine Hs Inhibitor Inhibition 6.5 pKd
neratinib Hs Inhibitor Inhibition 6.3 pKd
axitinib Hs Inhibitor Inhibition 6.0 pKd
NVP-TAE684 Hs Inhibitor Inhibition 5.7 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.


Reference: 1,4

Key to terms and symbols Click column headers to sort
Target used in screen: CSK/CSK
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
Lck inhibitor Hs Inhibitor Inhibition 3.4 0.0 -1.0
dasatinib Hs Inhibitor Inhibition 7.1
staurosporine Hs Inhibitor Inhibition 8.0 29.0 3.5
bosutinib Hs Inhibitor Inhibition 12.3
Src kinase inhibitor I Hs Inhibitor Inhibition 18.8 12.0 3.0
K-252a Hs Inhibitor Inhibition 31.1 71.0 18.0
nilotinib Hs Inhibitor Inhibition 42.4
TWS119 Hs Inhibitor Inhibition 43.6 79.0 21.0
PDGF receptor tyrosine kinase inhibitor IV Hs Inhibitor Inhibition 44.9 80.0 29.0
PP1 analog II Hs Inhibitor Inhibition 46.1 82.0 20.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Gene Expression and Pathophysiology Comments
An intronic CSK polymorphism (associated with increased CSK expression) is identified as a risk allele for SLE. Carriers of the risk allele show increased B-cell receptor (BCR)-mediated activation of mature B cells and a higher circulating immunoglobulin M level, compared to non-carriers [6].
Biologically Significant Variants
Type:  Single nucleotide polymorphism
Species:  Human
Description:  CSK intronic polymorphism rs34933034 is a risk allele for systemic lupus erythematosus.
SNP accession: 
References:  6


Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Bain J, McLauchlan H, Elliott M, Cohen P. (2003) The specificities of protein kinase inhibitors: an update. Biochem. J., 371 (Pt 1): 199-204. [PMID:12534346]

3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

5. Lamers MB, Antson AA, Hubbard RE, Scott RK, Williams DH. (1999) Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol., 285 (2): 713-25. [PMID:9878439]

6. Manjarrez-Orduño N, Marasco E, Chung SA, Katz MS, Kiridly JF, Simpfendorfer KR, Freudenberg J, Ballard DH, Nashi E, Hopkins TJ et al.. (2012) CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat. Genet., 44 (11): 1227-30. [PMID:23042117]

7. Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y et al.. (2015) Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2). J. Med. Chem., 58 (1): 183-96. [PMID:25075558]

8. Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci., 102 (7): 1374-80. [PMID:21443688]

9. Veillette A, Rhee I, Souza CM, Davidson D. (2009) PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. Immunol. Rev., 228 (1): 312-24. [PMID:19290936]

10. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Csk family: C-terminal Src kinase. Last modified on 23/05/2017. Accessed on 20/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1994.